Oura's first clinical trial will test whether ring data like sleep and resting heart rate can help care teams guide GLP-1 and bariatric surgery treatment.
Recap by typeshit. Full story at Wareable.
A Facebook share says Danish teams found certain bacterial strains may change how the gut tells the brain it is full. The work so far is in animal models only.
Bikman calls the results remarkable, but he argues that bigger drops make it more important to know how much of the lost weight is fat and how much is muscle.
Bikman points out that weight usually returns once the drug is stopped, which makes the question of lifelong use a real one.
Avi Roy flags a preprint that pooled 10,052 people from five semaglutide trials and used a blood test to estimate heart age. It has not yet been peer reviewed.
Two users describe their experiences with BPC-157 and peptide blends, while experts from McMaster and Rutgers warn that research-only products skip key safety checks.
NewBeauty shares the New York dermatologist's view on filler candidates. The excerpt gives no clear link to peptides or GLP-1 drugs.
Loading…